Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-Current Assets (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Non-Current Assets for 4 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 0.8% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.1 million through Dec 2025, up 8.53% year-over-year, with the annual reading at $6.9 million for FY2025, 0.8% down from the prior year.
  • Non-Current Assets for Q4 2025 was $6.9 million at Orchestra BioMed Holdings, down from $7.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $160.2 million in Q2 2022, with the low at $5.9 million in Q2 2024.
  • Average Non-Current Assets over 4 years is $29.9 million, with a median of $6.9 million recorded in 2025.
  • The sharpest move saw Non-Current Assets crashed 96.07% in 2023, then increased 17.64% in 2025.
  • Over 4 years, Non-Current Assets stood at $10.9 million in 2022, then plummeted by 43.96% to $6.1 million in 2023, then increased by 14.82% to $7.0 million in 2024, then decreased by 0.8% to $6.9 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $6.9 million, $7.0 million, and $6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.